Jaguar Health Completes Preferred Stock Conversion, Significantly Increasing Common Shares
JAGX sits 43% above its 52-week low of $2.12.
Summary
Jaguar Health announced the completion of its Series O Preferred Stock conversion into 4.86 million common shares, a highly dilutive event that significantly expands the company's outstanding share count.
Key Events · Financing and Capital Events · JAGX
-
Preferred Stock Conversion Completed
Jaguar Health finalized the conversion of all outstanding Series O Convertible Preferred Stock into common shares on June 25, 2026.
-
Significant Increase in Common Shares
The conversion resulted in 4,857,211 shares of common stock issued and outstanding.
-
Additional Shares from Warrants
Holders of eligible warrants are now entitled to receive up to an additional 839,000 common shares upon exercise.
-
Dilutive Capital Restructuring
This event actualizes a substantial increase in the common share base, following a history of dilutive financing and a recent reverse stock split.
Analysis · JAGX · Life Sciences
This 8-K reports the completion of a previously announced conversion of Series O Preferred Stock into common shares, a critical event for Jaguar Health's capital structure. The resulting 4.86 million common shares outstanding, with an additional 0.84 million shares issuable from warrants, represents a massive increase in the common share base. Given the company's recent history of financial distress, delisting threats, and highly dilutive financing, this conversion actualizes significant dilution for existing common shareholders.
At the time of this filing, JAGX was trading at $3.04 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.8M. The 52-week trading range was $2.12 to $97.65. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.